Direct characterization of a nonlinear photonic circuit's wave function with laser light

© The Author(s) 2018. Integrated photonics is a leading platform for quantum technologies including nonclassical state generation 1, 2, 3, 4, demonstration of quantum computational complexity 5 and secure quantum communications 6. As photonic circuits grow in complexity, full quantum tomography becomes impractical, and therefore an efficient method for their characterization 7, 8 is essential. Here we propose and demonstrate a fast, reliable method for reconstructing the two-photon state produced by an arbitrary quadratically nonlinear optical circuit. By establishing a rigorous correspondence between the generated quantum state and classical sum-frequency generation measurements from laser light, we overcome the limitations of previous approaches for lossy multi-mode devices 9, 10. We applied this protocol to a multi-channel nonlinear waveguide network and measured a 99.28±0.31% fidelity between classical and quantum characterization. This technique enables fast and precise evaluation of nonlinear quantum photonic networks, a crucial step towards complex, large-scale, device production

Relationship between erythema effective UV radiant exposure, total ozone, cloud cover and aerosols in southern England, UK

Evidence of an underlying trend in the dependence of erythema effective ultraviolet (UV) radiant exposure (Her) on changes in the total ozone, cloud cover and aerosol optical depth (AOD) has been studied using solar ultraviolet radiation measurements collected over a 25-year period (1991–2015) at Chilton in the south of England in the UK. The monthly mean datasets of these measures corrected for underlying seasonal variation were analysed. When a single linear trend was fitted over the whole study period between 1991 and 2015, the analyses revealed that the long-term variability of Her can be best characterised in two sub-periods (1991–2004 and 2004–2015), where the estimated linear trend was upward in the first period (1991–2004) but downward in the second period (2004–2015). Both cloud cover (CC) and total ozone (TO) were found to have a highly statistically significant influence on Her, but the influence of the AOD measure was very small. The radiation amplification factor (RAF) for the erythema action spectrum due to TO was −1.03 at constant levels of CC over the whole study period; that is, for a 1.0&thinsp;% increase in TO, Her decreases by 1.03&thinsp;%. Over the first period (1991–2004), the RAF related to CC was slightly higher at 0.97 compared to that for TO at 0.79. The proportion of the change in Her explained by the change in CC (47&thinsp;%) was much greater than the proportion explained by changes in TO (8&thinsp;%). For the second period (2004–2015), the pattern reversed, with the observed RAF related to TO being −1.25, almost double that of CC (−0.65). Furthermore, in this period the proportion of variation in Her explained by TO variation was 33&thinsp;%, double that of CC at 16&thinsp;%, while AOD changes had a negligible effect (1&thinsp;%). When the data were examined separately for each season, for the first period (1991–2004) the greatest effect of TO and CC on Her (i.e. the largest RAF value) was found during spring. Spring was also the season during which TO and CC variation explained the greatest proportion of variability in Her (82&thinsp;%). In the later period (2004–2015), the RAF and greatest influence of TO and CC were observed in winter (67&thinsp;%) and the AOD effect explained a further 5&thinsp;% variability in Her. This study provides evidence that both the increasing trend in Her for 1991–2004 and the decreasing trend in Her for 2004–2015 occur in response to variation in TO, which exhibits a small increasing tendency over these periods. CC plays a more important role in the increasing trend in Her for 1991–2004 than TO, whereas for 2004–2015, the decreasing trend in Her is less associated with changes in CC and AOD.</p

The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial

BACKGROUND Atypical meningiomas are an intermediate grade brain tumour with a recurrence rate of 39-58 %. It is not known whether early adjuvant radiotherapy reduces the risk of tumour recurrence and whether the potential side-effects are justified. An alternative management strategy is to perform active monitoring with magnetic resonance imaging (MRI) and to treat at recurrence. There are no randomised controlled trials comparing these two approaches. METHODS/DESIGN A total of 190 patients will be recruited from neurosurgical/neuro-oncology centres across the United Kingdom, Ireland and mainland Europe. Adult patients undergoing gross total resection of intracranial atypical meningioma are eligible. Patients with multiple meningioma, optic nerve sheath meningioma, previous intracranial tumour, previous cranial radiotherapy and neurofibromatosis will be excluded. Informed consent will be obtained from patients. This is a two-stage trial (both stages will run in parallel): Stage 1 (qualitative study) is designed to maximise patient and clinician acceptability, thereby optimising recruitment and retention. Patients wishing to continue will proceed to randomisation. Stage 2 (randomisation) patients will be randomised to receive either early adjuvant radiotherapy for 6 weeks (60 Gy in 30 fractions) or active monitoring. The primary outcome measure is time to MRI evidence of tumour recurrence (progression-free survival (PFS)). Secondary outcome measures include assessing the toxicity of the radiotherapy, the quality of life, neurocognitive function, time to second line treatment, time to death (overall survival (OS)) and incremental cost per quality-adjusted life year (QALY) gained. DISCUSSION ROAM/EORTC-1308 is the first multi-centre randomised controlled trial designed to determine whether early adjuvant radiotherapy reduces the risk of tumour recurrence following complete surgical resection of atypical meningioma. The results of this study will be used to inform current neurosurgery and neuro-oncology practice worldwide. TRIAL REGISTRATION ISRCTN71502099 on 19 May 2014

Anti-cancer effects and mechanism of actions of aspirin analogues in the treatment of glioma cancer

INTRODUCTION: In the past 25 years only modest advancements in glioma treatment have been made, with patient prognosis and median survival time following diagnosis only increasing from 3 to 7 months. A substantial body of clinical and preclinical evidence has suggested a role for aspirin in the treatment of cancer with multiple mechanisms of action proposed including COX 2 inhibition, down regulation of EGFR expression, and NF-κB signaling affecting Bcl-2 expression. However, with serious side effects such as stroke and gastrointestinal bleeding, aspirin analogues with improved potency and side effect profiles are being developed. METHOD: Effects on cell viability following 24 hr incubation of four aspirin derivatives (PN508, 517, 526 and 529) were compared to cisplatin, aspirin and di-aspirin in four glioma cell lines (U87 MG, SVG P12, GOS – 3, and 1321N1), using the PrestoBlue assay, establishing IC50 and examining the time course of drug effects. RESULTS: All compounds were found to decrease cell viability in a concentration and time dependant manner. Significantly, the analogue PN517 (IC50 2mM) showed approximately a twofold increase in potency when compared to aspirin (3.7mM) and cisplatin (4.3mM) in U87 cells, with similar increased potency in SVG P12 cells. Other analogues demonstrated similar potency to aspirin and cisplatin. CONCLUSION: These results support the further development and characterization of novel NSAID derivatives for the treatment of glioma

Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study

SummaryBackgroundThere is much uncertainty about the risks of leukaemia and lymphoma after repeated or protracted low-dose radiation exposure typical of occupational, environmental, and diagnostic medical settings. We quantified associations between protracted low-dose radiation exposures and leukaemia, lymphoma, and multiple myeloma mortality among radiation-monitored adults employed in France, the UK, and the USA.MethodsWe assembled a cohort of 308 297 radiation-monitored workers employed for at least 1 year by the Atomic Energy Commission, AREVA Nuclear Cycle, or the National Electricity Company in France, the Departments of Energy and Defence in the USA, and nuclear industry employers included in the National Registry for Radiation Workers in the UK. The cohort was followed up for a total of 8·22 million person-years. We ascertained deaths caused by leukaemia, lymphoma, and multiple myeloma. We used Poisson regression to quantify associations between estimated red bone marrow absorbed dose and leukaemia and lymphoma mortality.FindingsDoses were accrued at very low rates (mean 1·1 mGy per year, SD 2·6). The excess relative risk of leukaemia mortality (excluding chronic lymphocytic leukaemia) was 2·96 per Gy (90% CI 1·17–5·21; lagged 2 years), most notably because of an association between radiation dose and mortality from chronic myeloid leukaemia (excess relative risk per Gy 10·45, 90% CI 4·48–19·65).InterpretationThis study provides strong evidence of positive associations between protracted low-dose radiation exposure and leukaemia.FundingCenters for Disease Control and Prevention, Ministry of Health, Labour and Welfare of Japan, Institut de Radioprotection et de Sûreté Nucléaire, AREVA, Electricité de France, National Institute for Occupational Safety and Health, US Department of Energy, US Department of Health and Human Services, University of North Carolina, Public Health England